Angiotech Receives CE Mark Approval of Quill SRS MONODERM (T-Net British Columbia)
Vancouver, BC, October 12, 2007--(T-Net)--Angiotech Pharmaceuticals (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received CE Mark approval to begin marketing the Quill Self-Retaining System MONODERM sutures in Europe.

FDA approves fewer Indian copycat drugs (Express India)
The number of approved abbreviated new drug applications filed by Indian pharmaceutical companies-which have aggressively launched copycat versions of off-patent drugs in the US market-has declined dramatically in the last four months.

FDA To Speed Generic Drug Application Reviews (Medical News Today)
FDA on Thursday announced that it is implementing a number of changes to speed the approval process for generic drugs and reduce a backlog of more than 1,000 generic drug applications, the AP/Chicago Tribune reports. [click link for full article]